Evidence map›Paper›PMID 40719994›Full record

ReviewMedical oncology (Northwood, London, England)2025

Ruminococcus and prostate cancer: new treatment opportunities on the gut-prostate axis.

Yutong Liu, Yilin Wang, Guojun Wu, Yurong Tan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yutong Liu *Xiangya Medical College, Central South University, Changsha, China.
Yilin Wang *Xiangya Medical College, Central South University, Changsha, China.
Guojun WuXiangya Medical College, Central South University, Changsha, China. wuguojun@mail.csu.edu.cn.
Yurong TanXiangya Medical College, Central South University, Changsha, China. yurongtan@csu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ruminococcus, as a pivotal member of the gut microbiota, exhibits dual roles in the pathogenesis, progression, and treatment of prostate cancer (particularly castration-resistant prostate cancer, CRPC) through its metabolites, including short-chain fatty acids (SCFAs) and androgen steroids. This review highlights that Ruminococcus modulates prostate cancer development and therapy by metabolizing androgen precursors, secreting SCFAs, and influencing immune checkpoints. The findings provide reference data on the impact of Ruminococcus on prostate cancer and further propose novel therapeutic strategies, such as dietary interventions and microbiota modulation, to enhance treatment efficacy. Key mechanisms involve Ruminococcus-mediated reactivation of androgen receptor (AR) signaling post-androgen deprivation therapy (ADT), SCFA-induced autophagy and NF-κB/MAPK pathway activation, and strain-specific effects (e.g., R. gnavus associated with poor prognosis versus R. torques linked to improved CAR-T outcomes). These insights underscore the potential of targeting the gut-prostate axis for advancing precision oncology in CRPC management.

Indexed as

Gastrointestinal MicrobiomeProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantAnimalsFatty Acids, VolatileHumansMaleReceptors, AndrogenFatty Acids, VolatileReceptors, AndrogenAndrogen deprivation therapyAndrogen receptorProstate cancerRuminococcus

Identifiers

PMID40719994

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.